MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the year ending 2025-12-31.

Cash Flow Overview

Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Proceeds from term loan, net
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of marketable securiti...
    • Net accretion of investments in ...
    • Others

Cash Flow
2025-12-31
Net loss
-236,928
Stock-based compensation
29,876
Non-cash operating lease expense
1,892
Depreciation and amortization
208
Net accretion of investments in marketable securities
2,934
Impairment of held for sale assets
595
Loss on disposal of property and equipment
-47
Amortization of debt issuance costs and accretion of final payment fee
492
Amortization and write-off of deferred debt issuance costs
717
Other noncash expenses
32
Prepaid expenses and other current assets
2,770
Accounts payable
71
Accrued liabilities
4,195
Operating lease liabilities
-1,880
Other assets
53
Net cash used in operating activities
-206,440
Purchases of marketable securities
82,868
Cash paid for acquisition of assets
0
Proceeds from maturities of marketable securities
251,170
Proceeds from sale of property and equipment
218
Net cash provided by (used in) investing activities
168,520
Proceeds from term loan, net
57,161
Proceeds from exercise of stock options
0
Proceeds from employee stock purchase plan purchases
275
Proceeds from issuance of common stock in at-the-market transactions, net of commissions and offering costs
19,653
Net cash provided by financing activities
77,089
Net change in cash and cash equivalents and restricted cash
39,169
Cash and cash equivalents and restricted cash at beginning of year
143,361
Cash and cash equivalents and restricted cash at end of period
182,530
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof marketable...$251,170K Proceeds from term loan,net$57,161K Proceeds from issuance ofcommon stock in...$19,653K Proceeds from employeestock purchase plan...$275K Proceeds from sale ofproperty and equipment$218K Net cash provided by(used in) investing...$168,520K Net cash provided byfinancing activities$77,089K Canceled cashflow$82,868K Net change in cashand cash...$39,169K Canceled cashflow$206,440K Purchases of marketablesecurities$82,868K Stock-based compensation$29,876K Accrued liabilities$4,195K Non-cash operating leaseexpense$1,892K Amortization and write-off ofdeferred debt issuance...$717K Impairment of held for saleassets$595K Amortization of debt issuancecosts and accretion of...$492K Depreciation andamortization$208K Accounts payable$71K Loss on disposal ofproperty and equipment-$47K Other noncashexpenses$32K Net cash used inoperating activities-$206,440K Canceled cashflow$38,125K Net loss-$236,928K Net accretion ofinvestments in marketable...$2,934K Prepaid expenses andother current assets$2,770K Operating leaseliabilities-$1,880K Other assets$53K

Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics, Inc. (NMRA)